FDA Kicks Off Unapproved Drug Crack-Down With Carbinoxamine Enforcement
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is focusing initially on drugs containing the antihistamine carbinoxamine because of safety concerns in children.